Mitsubishi Tanabe Pharma America Announced the Presentations of its ND0612 in Parkinson’s Disease at 10th Congress of the European Academy of Neurology  

From Mitsubishi Tanabe Pharma America

Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs at Mitsubishi Tanabe Pharma America said, “We are excited to be at the Congress of the European Academy of Neurology (EAN) this year to showcase our  research and engage with its scientific community.

The findings highlight our dedication to advancing the understanding of investigational ND0612 and our commitment to recognizing the unmet needs of people living with Parkinson’s disease.”

Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma Corporation (MTPC) – the pharma arm of Mitsubishi Chemical Group (MCG), is one of the oldest pharmaceutical companies in the world, founded in 1678. MCG has positioned health care as its strategic focus in its management policy, “Forging the future”. MTPC sets the MISSION of “Creating hope for all facing illness”. To that end, MTPC is working on several disease areas.  MTPC is focusing on “precision medicine” to provide drugs with high treatment satisfaction and additionally working to develop “around the pill solutions” to address specific patient concerns based on therapeutic medicine, including prevention of diseases, pre-symptomatic disease care, prevention of aggravation and prognosis.

The Presentations include findings from subgroup analyses of the pivotal Phase 3 multi-center, randomized, double-blind double-dummy BouNDless trial (NCT04006210) evaluating the efficacy, safety and tolerability of investigational ND0612 in people with PD experiencing motor fluctuations, as well as a secondary analysis from a Phase 2 study (NCT02577523), which evaluated the onset of efficacy with ND0612 utilizing patient and clinical global ratings.

Presentation Details:

– Subgroup Analyses of a Phase 3, Randomized Study of Levodopa/Carbidopa Infusion (ND0612) for Parkinson Patients (Nelson Lopes,  M.D.; NeuroDerm)

e Presentation Session: “Movement Disorders 1” (EPR-082): 2:10 p.m. – 2:15 p.m. CEST, June 29.

– Onset of Efficacy with Levodopa/Carbidopa Infusion (ND0612) for Parkinson’s Patients 

(Nelson Lopes, M.D.; NeuroDerm)
ePresentation Session: “Movement Disorders 1” (EPR-083): 2:15 p.m. – 2:20 p.m. CEST, June 29

– Characterization of Infusion Site Reactions With 24-hour Subcutaneous Infusion of ND0612 

(Nelson Lopes, M.D.; NeuroDerm)
ePresentation Session: “Movement Disorders 1” (EPR-084): 2:20 p.m. – 2:25 p.m. CEST,June 29

ND0612 is an investigational drug-device combination therapy – a 24-hours/day, continuous subcutaneous (SC) infusion of liquid levodopa/carbidopa (LD/CD) for the treatment of motor fluctuations in people with Parkinson’s disease (PD). Development of investigational ND0612 is being led by NeuroDerm, Ltd., a wholly owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC).Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC). It was established by MTPC to develop and advance its pipeline as well as commercialize approved pharmaceutical products in North America.

About NeuroDerm, Ltd.

NeuroDerm, Ltd. is a wholly owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), based in Israel, inspired to reduce disease burden and improve the quality of life of patients and their families through innovative drug-device combination therapies and technologies. NeuroDerm is an integrated pharmaceutical and medical technology company developing central nervous system (CNS) product candidates.

Prohost Observations

Dementia’s complete root causes are near being discovered, including  Parkinson’s and Alzheimer’s Diseases. Pharmaceutical Companies are moving in an unparalleled speed towards discovering the secrets behind the lack of cognition in human beings’ minds.

We will post the names of the firms that focus on neurodegenerative diseases in one of the upcoming Prohost Letters.  

We find it impressive to learn that Mitsubishi Tanabe Pharma is one of the oldest pharmaceutical companies in the world.  The firm’s  pipeline comprises products for central nervous system diseases, immuno-inflammatory diseases and kidney diseases, in addition to diabetes and cancers. MTPC  precision enables the development of satisfactory therapeutics, which prevent or cure severe difficult-to-treat diseases. We will definitely have our eyes and ears on the 10th Congress of the European Academy of Neurology held at Helsinki, Finland, from June 29 – to July 2.

Leave a Reply